REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

One capsule daily. On Days 1-28 of repeated 28-day cycles.1

Start treatment at hematologic recovery and continue until disease progression or unacceptable toxicity.

REVLIMID® 10mg Capsule


10 mg on Days 1-28 of repeated 28-day cycles

Capsule shown not actual size.

If tolerated, dose can be increased to 15 mg after 3 cycles

Starting dose adjustments for renal impairment:

  • 5 mg once daily (CrCl 30-60 mL/min)
  • 2.5 mg once daily (CrCl <30 mL/min, not requiring or requiring dialysis*)
  • *On dialysis days, administer the dose following dialysis.


REVLIMID® Maintenance Dosing Modifications Based on Renal Function, Dose and Frequency

CrCl calculated based on Cockcroft-Gault equations. Capsules shown are not actual size.

Dosing for Patients with Renal Impairment

See recommendations for renally impaired patients, including patients on dialysis.

Dose Modifications for Adverse Events

See downloadable dose modifications for select adverse events.

Learn More
Dosing Guide

Use this guide to view the recommended dosing schedule and dose modifications.


Important Dosing Information

  • The capsules should not be opened, broken, or chewed
  • REVLIMID is primarily excreted unchanged by the kidney. Since elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Monitor renal function
  • Monitor CBCs every 7 days (weekly) for the first 2 cycles, on Days 1 and 15 of Cycle 3, and every 28 days (4 weeks) thereafter
  • Treatment is continued or modified based on clinical and laboratory findings
  • Dose modification guidelines are recommended to manage Grade 3/4 neutropenia or thrombocytopenia
  • For non-hematologic Grade 3/4 toxicities judged to be related to REVLIMID, hold treatment and restart at next lower dose level when toxicity has resolved to ≤Grade 2
  • Patients may require dose interruption and/or reduction
  • Patients may require the use of blood product support and/or growth factors

Help patients stay on REVLIMID Maintenance with dose modifications.

  • Until disease progression or unacceptable toxicity.


REVLIMID® Maintenance Dosing Modifications Neutropenia and Thrombocytopenia
  • Hematologic recovery: ANC >1000/mcL and/or platelet counts >75,000/mcL.
  • Do not dose below 5 mg daily for Days 1-21 of 28-day cycles.

For non-hematologic Grade 3/4 AEs, hold treatment and after resolution to ≤Grade 2, restart at next lowest dose.

  • AE, adverse event; ANC, absolute neutrophil count; CBC, complete blood count; CrCl, creatinine clearance.

Reference: 1. REVLIMID [package insert]. Summit, NJ: Celgene Corp.

Learn about the importance of continuous treatment.

View Continuous Treatment